- Home
- IAUX vs VOR Comparison
IAUX vs VOR Comparison
Compare IAUX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAUX | VOR |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IAUX | VOR |
|---|---|---|
| Price | $1.66 | $23.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $1.50 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 9.9M | 792.4K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | N/A |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 89.12 | N/A |
| 52 Week Low | $0.66 | $1.90 |
| 52 Week High | $2.24 | $49.95 |
Technical Indicators
Market Signals| Indicator | IAUX | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 60.97 |
| Support Level | $1.42 | $11.62 |
| Resistance Level | $1.95 | $24.34 |
| Average True Range (ATR) | 0.07 | 1.37 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 86.34 | 70.62 |
Price Performance
Historical ComparisonAbout IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.